It is the first to demonstrate that the combination of FA with MLT might alleviate ERS by activating AMPK, then down-regulating PPARγ and reducing the expression of Plin2 and Plin5, subsequently promoting LD lipolysis, decreasing LD accumulation, and ultimately achieving effective prevention of hepatic steatosis. The gene discussed is PPARG; the disease is Hepatic steatosis.